CD19

Cambridge, Massachusetts, U.S., October 26, 2026 CREATE Medicines, Inc. has announced a strategic research and development collaboration and licensing...

SAN DIEGO — September 9, 2026 Fate Therapeutics, Inc. announced that new clinical data for its off-the-shelf anti-CD19 CAR...

SOUTH SAN FRANCISCO, California — September 8, 2026 Nkarta, Inc. announced that three scientific presentations featuring NKX019 have been...

Tokyo, Japan, August 25, 2026 Astellas Pharma Inc. announced that the first patient has been dosed in a Phase...

Shanghai and Hong Kong, China, August 25, 2026 Antengene Corporation Limited announced that the Phase I ATTRACT clinical study...

NANJING, China, August 4, 2026 Leads Biolabs announced that its partner Oblenio Bio, a company jointly established with Aditum...

SHANGHAI and HONG KONG, China, July 13, 2026 Antengene has announced the receipt of a USD 60 million upfront...

SAN DIEGO, July 6, 2026 Fate Therapeutics announced that preliminary clinical data from its investigational FT819 off-the-shelf CD19-targeting CAR...

BOSTON, June 9, 2026 Imviva Biotech announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational...

SHANGHAI and HONG KONG, China, June 10, 2026 Antengene announced that China’s National Medical Products Administration (NMPA) has approved...